The Efficacy of Thoracic Erector Spinae Plane Block For Perioperative Analgesia in Laparoscopic Bariatric Surgery for Super Obese Patients.

Launched by AMANY AHMED EISSA · Apr 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to manage pain after laparoscopic bariatric surgery in super obese patients. The researchers want to see if a technique called the Erector Spinae Plane Block (ESPB), which uses ultrasound to guide the injection of a local anesthetic, can provide better pain relief compared to traditional methods. This is important because super obese patients often face challenges with pain management due to concerns about using opioids, which can lead to serious side effects.

To be eligible for this trial, participants should be adults aged 18 to 60 with a Body Mass Index (BMI) over 50, and they need to be scheduled for specific types of bariatric surgery, like sleeve gastrectomy or gastric bypass. Participants will receive either the ESPB or a local anesthetic injection at the surgery sites, and the researchers will monitor their pain levels and recovery. If you or a loved one meet these criteria and are considering bariatric surgery, this study could offer a promising approach to managing pain effectively and safely.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient age \>18 \<60
• • Super Obese patients ; Body mass index(BMI) \> 50 kg/m2
• • Both sexes
• • American Society of Anesthesiologists(ASA) physical status classes II and III
• • Patients scheduled for laparoscopic bariatric surgery i.e. sleeve gastrectomy and/or Roux-en-Y gastric bypass (RYGB)surgeries
• Exclusion Criteria:
• • • Refusal of regional block
• • Patients with neurological, psychological disorders or those lacking cooperation
• • Patients scheduled for concomitant laparoscopic cholecystectomy or paraumbilical hernia repair or those with history of previous bariatric surgery or obstructive sleep apnea
• • Patients with anatomic abnormalities at site of injection, skin lesions or wounds at site of proposed needle insertion.
• • Patients with bleeding disorders defined as (INR \>1.4) and/ or (platelet count \<100,000/µL)
• • Patients with hepatic disease e.g. liver cell failure or hepatic malignancy or hepatic enlargement.
• • Patients who are allergic to amide local anesthetics.
• • Cases converted to open surgery will also be excluded from the study